The life sciences sector is undergoing a profound transformation driven by the convergence of artificial intelligence and multi-omics technologies. Since 2026, the commercialization of AI in healthcare has accelerated markedly, with developments ranging from OpenAI's ChatGPT Health to a collaborative AI drug discovery lab established by NVIDIA and Eli Lilly, sparking surging interest in capital markets.
Concurrently, life science research continues to evolve. Cutting-edge technologies such as spatial omics, which provides spatial dimensional information, and long-read nanopore sequencing are complementing and synergizing with mainstream high-throughput sequencing technologies, collectively advancing precision medicine to new depths.
However, the global upstream life science tools market currently faces a significant challenge of "technological fragmentation." Technologies like short-read sequencing, long-read sequencing, spatial omics, and cellomics are often provided by different companies. This forces customers to purchase and integrate across multiple platforms for their research, leading to reduced efficiency, increased costs, and difficulties in data integration. The industry urgently needs platforms capable of offering integrated solutions to systematically enhance the effectiveness of both research and clinical applications. In this context, platform-based companies that can provide core tools and a data foundation in a one-stop manner are seeing their strategic value become increasingly prominent.
In February of this year, Mgi Tech Co.,Ltd. announced its intention to acquire 100% equity in Shenzhen Huada Sanjian Qifa Technology Co., Ltd. and Hangzhou Huada Xufeng Technology Co., Ltd. from its controlling shareholder for a total cash consideration of approximately 366 million yuan. On March 3rd, the proposal for this transaction was approved with a high majority vote at the company's extraordinary general meeting. The completion of this acquisition signifies that Mgi Tech has integrated the full-chain capabilities of two cutting-edge businesses: Sanjian Qifa's Stereo-seq spatial transcriptomics and Huada Xufeng's CycloneSEQ nanopore sequencing. This advancement positions Mgi Tech as the world's only life science tools manufacturer offering a full-stack product portfolio covering "all-read-length sequencing + intelligent automation + multi-omics."
From both financial and strategic perspectives, this acquisition represents more than just an addition of product lines and revenue. It is a crucial strategic move by Mgi Tech to position itself for the future trillion-yuan AI healthcare and multi-omics markets, paving the way for its long-term growth.
Notably, nanopore sequencing and spatial omics are core frontier technologies in life sciences, historically dominated by overseas giants. By internalizing and integrating these two advanced technologies through a cost-effective acquisition, Mgi Tech not only secures its next growth trajectory but also significantly strengthens its position in breaking international monopolies and supporting national strategic needs for biotechnology and data sovereignty.
The core strategic value of this acquisition lies first in the high degree of synergy between products and markets, firmly cementing Mgi Tech's position as the leader with the most comprehensive product portfolio and strongest overall capabilities in the global life science tools sector.
For Mgi Tech, which is already firmly established in the global high-throughput sequencing market, the best strategy to further consolidate its competitiveness involves not only deepening its existing expertise but also expanding horizontally across technology pathways. This approach allows it to capture market share in other technological areas while guarding against potential substitution by alternative technologies. Entering the nanopore sequencing and spatial omics sectors through this cost-effective acquisition represents a critical inflection point for unlocking future business synergies and breaking through market growth ceilings.
High-throughput sequencing and spatial transcriptomics have an upstream-downstream "synergistic" relationship. Spatial omics has gained significant attention in recent years. Stereo-seq, a spatial transcriptomics technology launched by BGI in 2020, is a hot area in basic research. Crucially, a complete Stereo-seq research workflow includes high-throughput sequencing, which is the forte of Mgi Tech's original business.
Instead of merely "defending" its position in high-throughput sequencing, Mgi Tech has demonstrated strategic foresight by incorporating these complementary and synergistic product lines into the listed company, forming a comprehensive toolkit. This enables Mgi Tech to offer customers more convenient, diverse, and integrated solutions, thereby enhancing both customer loyalty and market scale.
According to Mgi Tech's estimates, selling one unit of a spatial reagent kit can drive the sale of two units of its sequencing reagent kits. Furthermore, the spatial omics technology has gained high recognition from end-users due to its robust performance, leading to a virtuous cycle where customers purchasing the spatial omics products also procure Mgi Tech's sequencing instruments. This synergy continues to drive growth in both sales volume and revenue for complementary products. Market research indicates the global long-read sequencing market is growing at a compound annual growth rate of approximately 22%. Huada Xufeng's CycloneSEQ nanopore long-read sequencing technology, combined with Mgi Tech's existing DNBSEQ high-throughput sequencing technology, can form a complete SEQALL solution that complements short and long reads, better meeting diverse research and clinical needs and significantly enhancing market penetration.
Beyond product and technological synergy, the two acquired companies exhibit significant overlap with Mgi Tech in areas like supply chains and customer base. Post-merger, the company's bargaining power in procurement is expected to strengthen considerably, and the integration of overlapping functions will optimize overall operational efficiency. As integration deepens, the company's gross and net profit margins have the potential to increase, supporting sustained improvement in profitability.
The vast market prospects and product synergies form the strategic foundation of this acquisition. To translate this strategic potential into tangible returns for shareholders, the financial cost and risk of the transaction must be carefully considered. From this angle, the acquisition's design regarding valuation, payment structure, and risk control offers high strategic "value for money," evident in three key areas: significant valuation discount, prudent payment terms, and rigid performance commitments.
Firstly, the transaction valuation offers a substantial margin of safety. The combined valuation of the two target companies is approximately 366 million yuan. Based on their projected 2025 revenue, the combined price-to-sales ratio is only about 3x. This is significantly lower than the average valuation of comparable A-listed life science tools companies and represents a deep discount compared to overseas peers.
Secondly, the transaction structure involves a prudent staged payment plan, not a single lump sum. Only 70% of the consideration is payable upon completion, with the remaining 30% directly linked to the fulfillment of future performance targets by the acquired companies, effectively protecting the financial security of the listed entity.
More importantly, the counterparty has provided irrevocable performance commitments, guaranteeing a clear profit contribution. The two target companies are committed to achieving a cumulative net profit of no less than 132.9 million yuan between 2026 and 2030. Combined with the stable foundation of Mgi Tech's existing business and its global channel advantages, the company's overall revenue growth and profitability are poised to reach new levels, laying a solid foundation for valuation uplift. The agreement also includes strict asset impairment compensation clauses, effectively transferring common acquisition risks away from Mgi Tech and locking in future growth certainty with minimal capital risk.
Furthermore, the timing of the acquisition is strategic. Mgi Tech avoided the high-investment, high-risk "pioneering phase" of technology development and market validation for the target companies. By acquiring Sanjian Qifa and Huada Xufeng after they had finalized their products, built a global customer network spanning thousands of institutions, and were on the cusp of profitability, Mgi Tech bypassed the substantial time and trial-and-error costs associated with internal development.
On the surface, this acquisition appears to be a shrewd financial investment aimed at perfecting Mgi Tech's product matrix and solidifying its overall competitiveness. However, the true strategic ambition extends far beyond that.
With this move, Mgi Tech has not only assembled the world's only complete life science foundation technology chain—encompassing all-read-length sequencing, intelligent automation, and multi-omics—but has also secured a strategic entry point to the trillion-yuan AI healthcare market.
The explosion of cutting-edge applications like AI-powered pathological diagnosis and brain-computer interface research fundamentally relies on the supply of high-quality, standardized life science data. Current data supply faces multiple bottlenecks, including fragmentation across different institutions and systems with inconsistent standards and formats, hindering large-scale, high-quality integration, and insufficient dynamic updates, which impedes continuous algorithm iteration.
The high-quality, large-scale, multi-modal life data generated by Mgi Tech's full-chain life science equipment constitutes the essential raw material for training medical AI models. Simultaneously, Mgi Tech's intelligent automation platforms can standardize experimental workflows, enabling the efficient, stable, and scalable production of this critical data. This effectively addresses the data supply bottleneck for AI applications in life sciences. Mgi Tech's role is increasingly resembling that of NVIDIA in the AI era: an enabler driving industry-wide innovation by providing indispensable underlying infrastructure.
To date, Mgi Tech has supported over 49 large-scale population cohort projects globally. By the end of 2025, more than 17,968 scientific papers had been published based on data generated from its DNBSEQ gene sequencing platforms.
As AI in healthcare accelerates from research to clinical application, the demand for standardized, scalable life data will grow exponentially. Holding the complete chain from data production to intelligent analysis, Mgi Tech's strategic value and commercial moat as an upstream foundational player in AI healthcare will become increasingly prominent.
Against the backdrop of intensifying global technological competition, Mgi Tech's control over core frontier technologies like nanopore sequencing and spatial transcriptomics not only safeguards the security and resilience of the industrial chain but also secures strategic initiative for China at the level of global life science tools and data infrastructure.
From a corporate perspective, this acquisition represents not merely a business expansion but a strategic upgrade in role. Mgi Tech has built a complete product matrix covering all read lengths, multi-omics, and multiple scenarios, allowing it to seize a position of comprehensive strength in the global upstream life science tools market and the AI healthcare competition. Its growth narrative is evolving from singular technological leadership to comprehensive ecosystem leadership.
Comments